Doxycycline in Type II Diabetes
ConditionDiabetes Mellitus, Type 2
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age40-60
SponsorMostafa Bahaa
About this trial
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden
Eligibility criteria
Qualifiers
Male or female sex more than 40 years old Newly diagnosed type II diabetes. HbA1c more than 6.5
Disqualifiers
Patient with chronic kidney disease, hepatic disorders, mental and psychiatric disorders, pregnancy, and lactation
Trial design
Treatments tested in this trial
- Sitagliptin 100mg
- Doxycyclin
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Mostafa Bahaa
Lead sponsor
Tanta University
Sponsor institution
Source ClinicalTrials.gov